TY - JOUR
T1 - MRI to guide clinical management of rectal cancer
T2 - Updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)—PART I primary staging
AU - Stoker, Jaap
AU - Stocker-Ghafoor, Soleen
AU - Sen, Saugata
AU - Santiago, Inês
AU - Rodríguez Carnero, Pablo
AU - Rafaelsen, Søren R.
AU - Quaia, Emilio
AU - Ortega, Cinthia D.
AU - Nougaret, Stephanie
AU - Maas, Monique
AU - Lambregts, Doenja M.J.
AU - Lahaye, Max J.
AU - Laghi, Andrea
AU - Kim, Seung Ho
AU - Ippolito, Davide
AU - Horvat, Natally
AU - Hötker, Andreas M.
AU - Hoeffel, Christine
AU - Gurses, Bengi
AU - Gourtsoyianni, Sofia
AU - Gormly, Kirsten
AU - Goh, Vicky
AU - Gollub, Marc J.
AU - Dresen, Raphaëla C.
AU - Curvo-Semedo, Luís
AU - Crimì, Filippo
AU - Caruso, Damiano
AU - Blomqvist, Lennart
AU - Blazic, Ivana
AU - Beets-Tan, Regina G.H.
AU - Balyaniskova, Svetlana
AU - Ayuso, Juan Ramón
AU - ESGAR Rectal Imaging Guideline Group
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/6
Y1 - 2026/6
N2 - Objectives: To provide up-to-date consensus recommendations on the acquisition, interpretation and reporting of MRI for the primary staging of rectal cancer. Materials and methods: A panel of twenty-six abdominal imaging experts from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) engaged in an online consensus process, led by three non-voting chairs. The process adhered to an adapted version of the RAND-UCLA appropriateness method. A total of 126 items were scored (22 general, 55 on primary staging, 49 on restaging after neoadjuvant treatment) and classified using ≥ 80% as the cut-off to establish consensus. Results: Consensus was reached for 121 items (96%). The current manuscript addresses the resulting general recommendations and those focused on baseline staging. Key updates compared to the previous guideline editions include more detailed recommendations for image acquisition, adoption of the sigmoid take-off as a landmark to discern rectal from sigmoid cancer, updated definition of mesorectal fascia involvement by a distance of ≤ 1 mm, including involvement by irregular nodes and extramural vascular invasion; a transition to a patient-level approach for cN-category assessment with updated criteria for lateral nodes including a ≥ 7 mm size threshold, and recommendations on the limited use of DWI for primary staging. Conclusions: These updated expert consensus recommendations serve as clinical guidelines for the primary staging of rectal cancer using MRI. Recommendations for restaging and response evaluation after neoadjuvant treatment are addressed in a separate publication. Key Points: Question Since the last ESGAR rectal imaging guideline update, the rectal cancer treatment landscape has further evolved, necessitating updates to the existing guidelines. Findings An online consensus process involving 26 panellists led to 96% consensus across 121 items discussed, including 22 general items and 55 related to primary staging. Clinical relevance Key updates related to primary staging include more detailed recommendations for image acquisition, adoption of the sigmoid take-off, refined criteria for MRF involvement, a new patient-level approach for cN-assessment, and recommendations on the limited use of DWI.
AB - Objectives: To provide up-to-date consensus recommendations on the acquisition, interpretation and reporting of MRI for the primary staging of rectal cancer. Materials and methods: A panel of twenty-six abdominal imaging experts from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) engaged in an online consensus process, led by three non-voting chairs. The process adhered to an adapted version of the RAND-UCLA appropriateness method. A total of 126 items were scored (22 general, 55 on primary staging, 49 on restaging after neoadjuvant treatment) and classified using ≥ 80% as the cut-off to establish consensus. Results: Consensus was reached for 121 items (96%). The current manuscript addresses the resulting general recommendations and those focused on baseline staging. Key updates compared to the previous guideline editions include more detailed recommendations for image acquisition, adoption of the sigmoid take-off as a landmark to discern rectal from sigmoid cancer, updated definition of mesorectal fascia involvement by a distance of ≤ 1 mm, including involvement by irregular nodes and extramural vascular invasion; a transition to a patient-level approach for cN-category assessment with updated criteria for lateral nodes including a ≥ 7 mm size threshold, and recommendations on the limited use of DWI for primary staging. Conclusions: These updated expert consensus recommendations serve as clinical guidelines for the primary staging of rectal cancer using MRI. Recommendations for restaging and response evaluation after neoadjuvant treatment are addressed in a separate publication. Key Points: Question Since the last ESGAR rectal imaging guideline update, the rectal cancer treatment landscape has further evolved, necessitating updates to the existing guidelines. Findings An online consensus process involving 26 panellists led to 96% consensus across 121 items discussed, including 22 general items and 55 related to primary staging. Clinical relevance Key updates related to primary staging include more detailed recommendations for image acquisition, adoption of the sigmoid take-off, refined criteria for MRF involvement, a new patient-level approach for cN-assessment, and recommendations on the limited use of DWI.
KW - Clinical guidelines
KW - Magnetic resonance imaging
KW - Primary staging
KW - Rectal cancer
U2 - 10.1007/s00330-025-12274-w
DO - 10.1007/s00330-025-12274-w
M3 - Journal article
C2 - 41609770
AN - SCOPUS:105029481145
SN - 0938-7994
VL - 36
SP - 4592
EP - 4607
JO - European Radiology
JF - European Radiology
IS - 6
ER -